When is the Merck-TARGAN deal expected to close?

The expected closing date has not been announced.

TARGAN is a biodevice company focused on developing automated technology solutions for the poultry sector.

Merck Acquires TARGAN to Boost Poultry Tech Push

Merck (MRK) announced its Animal Health unit will acquire TARGAN, a biodevice company specializing in poultry solutions. The deal adds automated technology tools to Merck's animal health offerings. MRK shares are trading at $120.76.

June 12, 2026

1 min read

Source: Simply Wall St.

Key Numbers

share price

120.76

deal value

not disclosed

Merck's Animal Health unit has agreed to acquire TARGAN, a biodevice company focused on poultry solutions. The deal adds automated, technology-driven tools to Merck's animal health portfolio. Merck (NYSE:MRK) shares trade at $120.76.

Deal Details

Acquirer: Merck (Animal Health unit)
Target: TARGAN (poultry biodevice developer)
Value: Not disclosed
Payment method: Not specified
Expected close: Not announced

Rationale

The acquisition aims to bolster Merck's animal health offering with automated poultry technology. It underscores Merck's push into animal health innovation alongside its human health business.

Regulatory Hurdles

The deal is subject to regulatory review, but no major concerns have been raised publicly.

Stock Impact

Merck shares trade at $120.76. The deal may draw fresh attention to MRK, particularly if investors see growth potential in the animal health segment.

Frequently Asked Questions

The deal value has not been disclosed.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.